Reducing Hypersensitivity Reactions In Immunoglobulin Therapy with I2F

Hypersensitivity reactions during immunoglobulin (IG) therapy—ranging from mild rashes to life-threatening anaphylaxis—pose a significant risk to patient safety and contribute to increased healthcare costs. One often-overlooked cause of these reactions is protein aggregation, which is frequently triggered by the introduction of air bubbles during medication preparation and administration.

This white paper introduces I2F , a novel device engineered to eliminate air bubbles from IG solutions. By maintaining the integrity of protein structure and preventing aggregation, I2F significantly reduces the likelihood of infusion-related hypersensitivity events. The paper explores the underlying mechanisms of aggregation, the limitations of current stabilizers like Polysorbate 80, and how I2F provides a mechanical, non-chemical solution that improves clinical outcomes without altering drug formulations.

Through its ability to reduce adverse events, minimize premedication requirements, and prevent medication waste, I2F offers critical benefits for patients, healthcare providers, and IG manufacturers. By addressing a root cause of IG-related reactions, I2F sets a new standard for safety, reliability, and cost-efficiency in biologic drug administration.